2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Status
Withdrawn
1
Unknown
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Sarcoma
5
Gastrointestinal
4
Thoracic
2
Genitourinary
2
Breast
2
Other solid neoplasm
1
NET
1
Head & Neck
1
Endocrine
1
Conditions
Breast Neoplasms
13110
Triple Negative Breast Neoplasms
1145
Neoplasms
748
Ovarian Neoplasms
676
Neoplasm Metastasis
588
Lung Neoplasms
581
Colorectal Neoplasms
576
Prostatic Neoplasms
559
Carcinoma, Non-Small-Cell Lung
533
Pancreatic Neoplasms
380
Melanoma
366
Stomach Neoplasms
349
Colonic Neoplasms
330
Motor Activity
285
Breast Neoplasms, Male
285
Carcinoma, Intraductal, Noninfiltrating
277
Uterine Cervical Neoplasms
265
Head and Neck Neoplasms
265
Endometrial Neoplasms
254
Carcinoma, Renal Cell
215
Sarcoma
202
Urinary Bladder Neoplasms
192
Squamous Cell Carcinoma of Head and Neck
190
Lymphedema
190
Breast Carcinoma In Situ
189
Esophageal Neoplasms
188
Brain Neoplasms
183
Fatigue
166
Carcinoma, Ovarian Epithelial
151
Breast Cancer Female
148
Interventions
regorafenib
1
brigimadlin
1
Clinical Trials, Phase II as Topic
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Tertiary Lymphoid Structures
×
Breast
×
Clear all
NCT06084689
2025-09-02
EMPIRE
Institut Bergonié
Phase 2
Withdrawn
NCT03475953
2023-03-03
REGOMUNE
Institut Bergonié
Phase 1/2
Unknown
747 enrolled